Itraconazole: The Antifungal With Phase II Cancer Data

The Bottom Line

Itraconazole is an antifungal with serious cancer data that most people don't know about. A Johns Hopkins Phase II trial in metastatic castration-resistant prostate cancer (mCRPC) showed 48% PSA progression-free survival at 24 weeks at high dose. The mechanism isn't antifungal — it hits Hedgehog signaling, VEGFR2, and mTOR simultaneously. Three targets, one generic drug.

What It Is

Itraconazole (Sporanox) is an FDA-approved triazole antifungal used for histoplasmosis, aspergillosis, and onychomycosis. What makes it interesting for cancer is that it was serendipitously found to inhibit the Hedgehog signaling pathway during antifungal development. Unlike other antifungals, itraconazole also inhibits VEGFR2 (angiogenesis) and mTOR. This multi-target profile is unusual for a single compound.

The Evidence

Phase II Prostate Cancer Trial (Johns Hopkins)

Antonarakis et al. conducted a randomized Phase II trial at Johns Hopkins in 46 men with metastatic castration-resistant prostate cancer (mCRPC). Patients were randomized to low-dose (200mg/day) or high-dose (600mg/day) oral itraconazole.

• High-dose arm results: 48% were PSA progression-free at 24 weeks. Median progression-free survival was 35.9 weeks.
• 14.3% had a confirmed PSA response
• Low-dose arm: Stopped early for futility — lower dose was insufficient
• Mechanism confirmation: Skin biopsies confirmed Hedgehog pathway inhibition in vivo

Source: PMC3579600

NSCLC and Other Cancers

Preclinical work showed 72-79% tumor growth reduction in NSCLC xenograft models. The dual Hedgehog + VEGFR2 inhibition gives itraconazole anti-angiogenic properties beyond what single-target agents achieve. Phase II trials in basal cell carcinoma showed measurable responses. A trial in triple-negative breast cancer (NCT02000492) is listed on ClinicalTrials.gov.

Grade Rationale

Grade B because there is a well-conducted Phase II RCT at Johns Hopkins with a confirmed mechanism (Hedgehog pathway inhibition documented via skin biopsy). The primary endpoint was met (PSA progression-free at 24 weeks). However, this is still a single Phase II trial in one cancer type. Larger trials or trials in other cancer types would move this to Grade A.

Mechanism

• Hedgehog pathway inhibition: Itraconazole acts as a potent SMO antagonist, blocking the Hedgehog transcription factors GLI1 and GLI2. This pathway is abnormally active in many cancers including prostate, basal cell, and medulloblastoma.
• VEGFR2 inhibition: Anti-angiogenic effect by blocking vascular endothelial growth factor receptor 2. Tumors need new blood vessels to grow beyond 1-2mm.
• mTOR inhibition: Blocks the mTOR pathway via a different mechanism than rapamycin — through cholesterol trafficking rather than FKBP12 binding.

Practical Considerations

The high dose used in the positive arm (600mg/day) is substantially higher than typical antifungal dosing. This requires a doctor's supervision. Itraconazole has significant drug interactions (CYP3A4) and can cause liver toxicity. The FDA black box warning for heart failure is relevant at high doses. It also requires acidic gastric conditions for absorption — PPIs and H2 blockers reduce absorption significantly. Take with food.

Our Assessment

Itraconazole is one of the most interesting off-patent drugs for prostate cancer that nobody talks about. The Antonarakis trial is real, the mechanism is validated, and 48% PFS at 24 weeks in a hard-to-treat population is meaningful. Worth discussing with a urologist or oncologist if you have mCRPC and are looking for adjuncts. Do not self-prescribe — the dosing and drug interaction issues are serious.

Sources

• PMC3579600: Itraconazole and prostate cancer (Antonarakis et al., Johns Hopkins Phase II)
• ClinicalTrials.gov NCT02000492: Itraconazole in triple-negative breast cancer
• Oncotarget 2014: Itraconazole as a novel anticancer drug
• British Journal of Cancer 2016: VEGFR2 and Hedgehog dual inhibition